Spectrascience, Inc. (OTC: SCIE) develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy. The company’s WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the System is the first commercially available product that incorporates this technology for clinical use. WavSTAT recently received regulatory marketing approval in Saudi Arabia. For more information, visit the company’s website at www.spectrascience.com.